AstraZeneca at ASCP 2026
Nov 17–20, 2026 Montréal, Canada ~1.5k attendees Website
AstraZeneca takes part in 3 sessions at ASCP 2026 in Montréal, and exhibits at Booth 208. Its program covers biomarker testing for cancer: reading and scoring HER2 staining in metastatic breast cancer, HER2 testing in other solid tumors and PTEN testing in metastatic prostate cancer.
| Organization | ASCP 2026 Attendance |
|---|---|
AstraZeneca Cambridge, UK | ◆Diamond Sponsor |
Global pharmaceutical company whose oncology medicines rely on biomarker tests such as HER2 and PTEN read by pathologists. | Booth Exhibiting at Booth 208 Wed, Nov 1810am–4pmThu, Nov 199–11am · 12:15–3pm Talk Wed Nov 18 12–1pm Talk Thu Nov 19 7–8am Talk Fri Nov 20 12–1pm |
Find decision makers at AstraZeneca
Tell us what you sell and we’ll find the people at AstraZeneca most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society for Clinical Pathology (ASCP) or the Canadian Association of Pathologists (CAP-ACP). Organization details are derived from the meeting’s published program, faculty list, poster list and exhibitor list, and each organization’s own website. Submit a correction